Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome.
OBJECTIVE
To determine the effect of treatment with vitamin D(3) analogue in the parameters of glucose metabolism in obese women with polycystic ovary syndrome (PCOS).


METHODS
Observational study.


METHODS
Obese women with PCOS in an academic research environment.


METHODS
Fifteen obese women (mean age 28 +/- 1.3 years, mean body mass index 32.55 +/- 0.43) with documented chronic anovulation and hyperandrogenism were recruited into the study.


METHODS
Alphacalcidol (1-alpha-hydroxyvitamin D(3)) was administered orally 1 microg/day for 3 months. All subjects underwent a frequently sampled IV glucose tolerance test after a 10- to 12-hour overnight fast during a spontaneous bleeding episode before and after treatment with alphacalcidol.


METHODS
Peripheral insulin resistance and insulin effectiveness were estimated with minimal model.


RESULTS
The first phase of insulin secretion was significantly increased after treatment with alphacalcidol. A favorable statistically significant change also was observed in the lipid profile.


CONCLUSIONS
Treatment with the vitamin D(3) analogue (alphacalcidol) could be of value in the management of PCOS.
Kotsa
Kalliopi
K
Division of Endocrinology and Metabolism, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece.
Yavropoulou
Maria P
MP
Division of Endocrinology and Metabolism, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece.
Anastasiou
Olympia
O
Division of Endocrinology and Metabolism, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece.
Yovos
John G
JG
Division of Endocrinology and Metabolism, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece. Electronic address: giovos@med.auth.gr.
D000328:Adult; D001786:Blood Glucose / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use; D002118:Calcium / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D005947:Glucose / Q000378:metabolism*; D005951:Glucose Tolerance Test; D006801:Humans; D006887:Hydroxycholecalciferols / Q000494:pharmacology / Q000627:therapeutic use; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology; D050356:Lipid Metabolism / Q000187:drug effects; D009765:Obesity / Q000378:metabolism / Q000503:physiopathology; D010281:Parathyroid Hormone / Q000097:blood; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology*; D014807:Vitamin D / Q000031:analogs & derivatives / Q000502:physiology*
D001786:Blood Glucose; D050071:Bone Density Conservation Agents; D006887:Hydroxycholecalciferols; D007328:Insulin; D010281:Parathyroid Hormone; D014807:Vitamin D; D005947:Glucose; D002118:Calcium; C008088:alfacalcidol